The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor Debio 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor–positive (HR+)/HER2-negative (HER2–) advanced breast cancer (ABC): The WIN-B study.
 
Timothy Robinson
No Relationships to Disclose
 
Maria Gion
No Relationships to Disclose
 
Isabel Blancas
No Relationships to Disclose
 
Meritxell Aguiló
No Relationships to Disclose
 
Juliana Santos
No Relationships to Disclose
 
Sandra Santasusagna
No Relationships to Disclose
 
Michela Verbeni
No Relationships to Disclose
 
Esteban Rodrigo Imedio
Employment - Debiopharm Group
Patents, Royalties, Other Intellectual Property - Patents from Debio 0123 from Debiopharm International
 
Luke Piggott
Employment - Debiopharm Group
Patents, Royalties, Other Intellectual Property - Patrients from Debiopharm
 
José Manuel Pérez García
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Gilead Sciences; Lilly; MSD Oncology; Roche; Seattle Genetics/Astellas
Other Relationship - MEDSIR
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Circle Pharma; Clovis Oncology; Daiichi Sankyo; Delcath Systems; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; Hexagon Bio; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics
 
Antonio Llombart-Cussac
Honoraria - AstraZeneca Spain; Daiichi Sankyo Europe GmbH; Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Agendia; AstraZeneca Spain; Gilead Sciences; Guardant Health; Lilly; Menarini; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Gilead Sciences
Research Funding - Novartis (Inst); Roche/Genentech (Inst)
Expert Testimony - Menarini
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Lilly; MSD Oncology; Pfizer; Roche